Beyond Air Earnings Call Signals Momentum Amid Risks

Beyond Air ((XAIR)) has held its Q3 earnings call. Read on for the main highlights of the call.

Beyond Air’s latest earnings call struck a cautiously optimistic tone as management highlighted accelerating revenue growth, improving margins, and disciplined cost cuts, even as losses and cash burn remain material. Executives emphasized that operational momentum, expanding hospital adoption, and progress toward a next‑generation device are beginning to change the trajectory of the business.

Strong Revenue Growth

Beyond Air reported quarterly revenue of $2.2 million, up 105% year over year from $1.1 million and 21% sequentially, signaling real traction off a small base. Management framed the growth as evidence that LungFit PH is gaining acceptance in both U.S. and international markets despite long sales cycles.

Gross Profit Turnaround

The company delivered a notable gross profit swing, moving from a $200,000 loss in the year‑ago quarter and a $300,000 loss last quarter to a $300,000 gross profit. While the implied ~14% gross margin is still low, leadership argued it validates progress on pricing, utilization, and early scale benefits.

Lean Cost Structure and Smaller Net Loss

Operating expenses fell to about $6.9 million, down 36% from $10.7 million a year ago and more than 60% below the $17 million peak, reflecting sharp spending discipline. As a result, net loss attributable to common shareholders narrowed to $7.3 million, roughly a 44% improvement versus the prior year’s $13 million loss.

Improved Cash Burn and Runway

Net cash burn dropped more than 40% year over year to $4.3 million for the quarter, easing immediate liquidity pressure. With $17.8 million in cash and securities at year‑end plus a January equity raise, management now believes it has funding into 2027, assuming revenue growth and cost targets are met.

Commercial Traction and Global Footprint

LungFit PH is now in more than 45 hospitals worldwide, with customer retention above 90% and over half of clients on multiyear contracts, supporting recurring revenue. U.S. reach is expanding through GPO deals with Premier and Vizient and an initial VA sale, while distribution now spans 40 countries with early repeat orders.

Gen II LungFit PH as a Key Catalyst

Management is preparing for a second‑generation LungFit PH, targeting FDA review by the end of 2026, contingent on regulatory timelines. Gen II is designed to be smaller, easier to use, and more durable, with longer service intervals and better transport compatibility, all expected to open new use cases and drive higher margins.

NeuroNOS Deal to Unlock Noncore Value

Beyond Air signed a binding letter of intent to sell its majority stake in NeuroNOS to XTL Biopharmaceuticals in exchange for equity, cash, and potential milestones. Executives said the transaction is meant to shift funding responsibility for the neurology asset while retaining upside for shareholders and allowing management to concentrate on core respiratory commercialization.

Small Revenue Base and Ongoing Losses

Despite headline growth rates, absolute revenue remains modest at $2.2 million and the company is still far from breakeven. Continued net losses and negative free cash flow mean execution on growth and cost controls will be critical to avoid further dilution or funding pressure.

Margin Gap to Long‑Term Targets

The current 14% gross margin stands well below management’s long‑term goals of roughly 50–60% for Gen I and about 70% for Gen II as volumes scale. Closing that gap will depend on ramping utilization, shifting mix to higher‑margin Gen II units, and realizing efficiencies from longer service intervals and better logistics.

Regulatory and Manufacturing Timing Risks

The timeline for Gen II remains tied not just to FDA review but also to inspection of the contract manufacturer, which management called a gating item. Any delay in that inspection or regulatory feedback could push out the expected late‑2026 clearance and, by extension, revenue and margin inflection.

Slow and Variable Sales Cycle

Executives acknowledged that the typical 6–9 month, and sometimes longer, sales cycle for LungFit PH can mute near‑term growth despite interest from hospitals. While some contracts close in 4–5 months, this variability could keep quarterly revenue lumpy and complicate forecasting in the near term.

Uncertain Oncology and Neuro Timelines

Beyond Air continues to advance its oncology program, with Phase Ib data headed for a major oncology meeting, but larger trials are unlikely to be fully funded until the core business is stronger. The NeuroNOS transaction, if completed, would offload funding needs, yet the timing and ultimate realization of contingent value remain uncertain.

Disclosure Clarity Concerns

Some figures around financing proceeds and potential NeuroNOS milestone amounts were described with slightly different totals at various points in the call. While not financially material at this stage, such inconsistencies could raise questions about communication precision among more detail‑oriented investors.

Guidance and Outlook

Looking ahead, management expects revenue momentum to continue and is targeting FDA clearance and launch of Gen II LungFit PH by the end of 2026 while expanding Gen I usage. The company aims to lift gross margins toward the 50–70% range over time and believes existing capital, supplemented by facilities in place, could carry it into 2027 and potentially to profitability if plans stay on track.

Beyond Air’s earnings call painted a picture of a company transitioning from early commercialization to more scalable operations, with tangible progress in revenue, margins, and cost control. Yet with small absolute sales, continuing losses, and regulatory dependencies, investors will be watching closely to see if the current momentum can sustain and ultimately translate into durable profitability.